Lupin Ltd Share Price

Lupin faces pressure as Citi turns bearish

Lupin Ltd. Investment Update: Divergent Analyst Perspectives

Lupin - A failed Rounding bottom Breakout - Trapped Investor

Lupin Secures USFDA Approval for Generic Pitolisant

Lupin Limited has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths. Determined to be bioequivalent to the reference product Wakix—which is marketed by Harmony Biosciences—the medication is indicated for the treatment of excessive daytime sleepiness (EDS). This regulatory milestone significantly bolsters Lupin's generic portfolio in the crucial US healthcare market while broadening its therapeutic footprint in sleep-related disorders. The approval highlights Lupin's ongoing strategy to expand its lineup of specialized generic therapeutics across regulated global markets. By meeting rigorous USFDA equivalence standards through the ANDA pathway, the company introduces a viable generic alternative for patients experiencing excessive daytime sleepiness. This addition enables Lupin to capture market share within the US sleep-disorder segment, reinforcing the broader role of Indian pharmaceutical firms in delivering accessible, high-value generic medicines internationally.

Can GLP-1 drugs change India’s productivity story?

A drug can change more than a patient’s weight. It can change how often someone misses work. A recent Danish study of Ozempic users found that long-term sick leave fell after treatment, while employment itself did not meaningfully increase. The important lesson: better health does not automatically translate into more jobs or higher income—but it may help people stay healthier and more consistently at work. Now India is running a much bigger real-world experiment. Semaglutide’s key Indian patent expired in March 2026, opening the market to a wave of cheaper generic versions. Companies including Sun Pharma, Dr. Reddy’s Laboratories, Zydus Lifesciences, Lupin, Alkem, Torrent Pharma and Natco Pharma have entered or developed products in this space. For investors, the interesting question isn't simply: “Who will sell the most GLP-1 drugs?” It is: Who can convert the GLP-1 opportunity into sustainable volumes, margins and market share? Sun Pharma

Daily Index View : BANKNIFTY as on 24/08/2026

1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 -10% 🔍 Key Level to Watch: 57430 🔄 Current Market Surface: The trend will stay Positive until the market stay above 57430 That’s 332 points away from the last day Closing Price of 57762 ATR 495 2. Demand & Supply PROBABILITY Force is Demand & Supply is High -15% Last 3 days market has been flatish on downside compared to ATR, so supply has very strong firepower — it just needs sentiment support 21 Aug 2026 FII Cash-net (Buy/sell) DII Cash- net (BUY/SELL) -543 +2,124.14 3. Reflexivity PROBABILITY First Half is Mildly Supportive to Bullish Momentum for at least first half 5% Last day market rallied Intraday around 25–50% of the 8-day average ATR, so it should keep its momentum intact in the first half 4. Social Proof (Global) PROBABILITY Dow Jones (Last day close) 48185 Up/Donw by 508 -1% Dow jones future (live) 53,380 Up/Donw by +27.0 Hang seng (Live) 26009 Up/Donw by -492 Nikki 225 (Live) 65528 Up/Donw by -488 Sentiments: Dow Jones Futures is Trading Flat to Positive & HANG SENG Index is trading Extremely Negative Today, global markets are neutral to slightly positive, and the Indian market has no strong directional bias Top stock to watchout